Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



Knockout Drugs: Ocrelizumab and Biotin

The ECRTIMS Program listings look like the image above

It’s that time again for the MS specialists, researchers, nurses, therapists and journalists to gather for the annual ECTRIMS conference. ECTRIMS, short for the European Committee for the Treatment and Research in Multiple Sclerosis, is THE premiere conference, where the various interests gather to learn about a wide variety of treatment options, hear about breaking news from the researchers, and in general immerse themselves in all things MS for a few days with their peers.

Very few of us lay people who would like to attend are able to go to ECTRIMS, primarily because of the logistics and expense of getting to Europe; this year’s conference is in Barcelona.  Instead of drinking Sangria and eating tapas in Spain, we wait for the headlines and press releases to tell us the big stories breaking at ECTRIMS. We get hints in advance, thanks to the public relations agencies and the  advance notices, and this year is no different.

Many of us also spend hours reviewing the program guide, which is available online. These program books make for interesting reading because they give insight into the types of classes and work our medical team puts into staying on top of the latest advances in treatment. It is also sometimes possible to spot the BIG stories that might generate headlines, and this year is no different. On the schedule on Saturday, Oct 10, under the sessions marked LATE BREAKING NEWS, appears two studies I want to know more about and I know most everyone living with MS will be interested in, too.

Two Primary Progressive MS treatments about Ocrelizumab and Biotin, have yielded promising results through clinical trials and these two newsworthy studies are part of the Late Breaking News. I still don’t understand how ‘late breaking’ this news can be if it is printed in the program, so there must be something to this title. Oddly, these study presentations appear in the program book directly opposite each other on pages 64-65, while earlier today I read about the parent companies of these two studies in a stock market report and how they will be battling each other in the marketplace.

Public discussion about both of these drugs for treating Primary Progressive MS has been circulating widely this year and it is easy to find more information online about these trials. Here are two examples-
Medday’s MD1003 hits ‘ambitious’ endpoints in its MS phase III trial was reported at the American Academy of Neurology meetings earlier this year. Genentech’s Ocrelizumab First Investigational Medicine to Show Efficacy in People with Primary Progressive Multiple Sclerosis in Large Phase III Study is the official release regarding Ocreluzimab trial results.

Meanwhile, on the financial side of this news, Reuters news service reported in their stock news headlines-

Roche gets jump on rivals in race for progressive MS treatment

* French firm MedDay says plans to file rival drug in 2016

* Roche (Symbol: RHHV)  claims “significant first” in difficult-to-treat MS

“… Roche looks likely to enjoy a first-mover advantage, creating a multibillion-dollar opportunity for ocrelizumab in both relapsing remitting MS (RRMS) and progressive disease.”

Story Source: The above story is based on materials provided by MULTIPLESCLEROSIS.NET
Note: Materials may be edited for content and length

Go to Newer News Go to Older News